Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...

“Without FDA approval, consumers must rely on their own research to evaluate and identify trustworthy brands,” notes Will ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Greetings, and welcome to the Achieve Life Sciences Third Quarter ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

From STAT’s Elaine Chen: Earlier this month, the FDA updated the labels of GLP-1 drugs to warn of the risk of patients ...